...
首页> 外文期刊>American Journal of Physiology >Role of PAC(1) receptor in adrenal catecholamine secretion induced by PACAP and VIP in vivo.
【24h】

Role of PAC(1) receptor in adrenal catecholamine secretion induced by PACAP and VIP in vivo.

机译:PAC(1)受体在PACAP和VIP体内诱导的肾上腺儿茶酚胺分泌中的作用。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The present study was conducted to investigate the functional implication of the pituitary adenylate cyclase-activating polypeptide (PACAP) type I (PAC(1)) receptor in the adrenal catecholamine (CA) secretion induced by either PACAP-27 or vasoactive intestinal polypeptide (VIP) in anesthetized dogs. PACAP-27, VIP, and their respective antagonists were locally infused to the left adrenal gland via the left adrenolumbar artery. Plasma CA concentrations in adrenal venous and aortic blood were determined by means of a high-performance liquid chromatograph coupled with an electrochemical detector. Adrenal venous blood flow was measured by gravimetry. The administration of PACAP-27 (50 ng) resulted in a significant increase in adrenal CA output. VIP (5 microg) also increased the basal CA secretion to an extent comparable to that observed with PACAP-27. In the presence of PACAP partial sequence 6--27 [PACAP-(6--27); a PAC(1) receptor antagonist] at the doses of 7.5 and 15 microg, the CA response to PACAP-27 was attenuated by approximately 50 and approximately 95%, respectively. Although the CA secretagogue effect of VIP was blocked by approximately 85% in the presence of PACAP-(6--27) (15 microg), it remained unaffected by VIP partial sequence 10--28 [VIP-(10--28); a VIP receptor antagonist] at the dose of 15 microg. Furthermore, the CA response to PACAP-27 did not change in the presence of the same dose of VIP--(10--28). The results indicate that PACAP-(6--27) diminished, in a dose-dependent manner, the increase in adrenal CA secretion induced by PACAP-27. The results also indicate that the CA response to either PACAP-27 or VIP was selectively inhibited by PACAP-(6--27) but not by VIP-(10--28). It is concluded that PAC(1) receptor is primarily involved in the CA secretion induced by both PACAP-27 and VIP in the canine adrenal medulla in vivo.
机译:进行本研究以调查垂体腺苷酸环化酶激活多肽(PACAP)I(PAC(1))受体在PACAP-27或血管活性肠多肽(VIP)诱导的肾上腺儿茶酚胺(CA)分泌中的功能含义)在麻醉的狗中。 PACAP-27,VIP及其各自的拮抗剂通过左肾上腺腰动脉局部注入到左肾上腺。肾上腺静脉和主动脉血中血浆CA浓度是通过高效液相色谱仪和电化学检测器相结合测定的。通过重量分析法测量肾上腺静脉血流量。 PACAP-27(50 ng)的使用导致肾上腺CA产量显着增加。 VIP(5微克)也增加了基础CA的分泌,其程度与PACAP-27观察到的相当。在存在PACAP部分序列6--27 [PACAP-(6--27); [PAC(1)受体拮抗剂]的剂量为7.5和15微克,CA对PACAP-27的反应分别减弱了约50%和约95%。尽管在存在PACAP-(6--27)(15 microg)的情况下VIP的CA促分泌素作用被大约85%阻断,但仍不受VIP部分序列10--28 [VIP-(10--28)的影响; VIP拮抗剂]的剂量为15微克。此外,在相同剂量的VIP-(10--28)的存在下,CA对PACAP-27的反应没有改变。结果表明,PACAP-(6--27)以剂量依赖的方式减少了由PACAP-27诱导的肾上腺CA分泌的增加。结果还表明,CACAP对PACAP-27或VIP的反应被PACAP-(6--27)选择性抑制,而VIP-(10--28)则没有。结论是,PAC(1)受体主要参与犬肾上腺髓质中PACAP-27和VIP诱导的CA分泌。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号